Tissue Regenix Group PLC (AIM:TRX) said that first-half trading met expectations with revenues growing 16% to $16.4 million - the seventh consecutive growth period.
Following its first year of adjusted EBITDA profitability in 2023, the group anticipates further adjusted growth in earnings in the six months ended June 30.
The regenerative medicines group said the BioRinse segment showed solid growth thanks to increased efficiencies, and added the dCELL segment's commercial reorganisation continued to yield benefits.
"After delivering maiden profitability with our FY 2023 numbers, it is particularly pleasing to announce another period of progress, not only financially but also operationally," said chief executive, David Lee.
"Our 4S strategy continues to deliver benefits, and our tactical growth pillars should drive further growth and deliver the results that are expected by our stakeholders. We are firmly committed and confident in keeping Tissue Regenix on its positive trajectory, which began in 2021."
Lee's '4S' strategy has seen the company focus on supply, sales revenue, sustainability and scale.